NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis $8.43 +0.15 (+1.81%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.26▼$8.5750-Day Range$4.93▼$8.4352-Week Range$2.00▼$11.31Volume799,092 shsAverage Volume2.27 million shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$15.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ocular Therapeutix alerts: Email Address Ocular Therapeutix MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside87.8% Upside$15.83 Price TargetShort InterestBearish13.16% of Shares Sold ShortDividend StrengthN/ASustainability-2.01Upright™ Environmental ScoreNews Sentiment0.71Based on 4 Articles This WeekInsider TradingSelling Shares$13,280 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.98) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.85 out of 5 starsMedical Sector215th out of 936 stocksPharmaceutical Preparations Industry90th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingOcular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 4 research reports in the past 90 days.Read more about Ocular Therapeutix's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.16% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 4.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOcular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ocular Therapeutix is -2.01. Previous Next 2.1 News and Social Media Coverage News SentimentOcular Therapeutix has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ocular Therapeutix this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows8 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,280.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ocular Therapeutix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ocular Therapeutix are expected to grow in the coming year, from ($0.98) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -6.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -6.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 10.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ocular Therapeutix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Ocular Therapeutix Stock (NASDAQ:OCUL)Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Read More OCUL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCUL Stock News HeadlinesJuly 25 at 4:18 AM | americanbankingnews.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 23 at 11:47 AM | seekingalpha.comOcular Therapeutix: A Speculative Investment For Risk-Tolerant InvestorsJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 19, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 19, 2024 | americanbankingnews.comComparing Phathom Pharmaceuticals (NASDAQ:PHAT) & Ocular Therapeutix (NASDAQ:OCUL)July 18, 2024 | globenewswire.comOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 10, 2024 | globenewswire.comOcular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific MeetingJuly 8, 2024 | globenewswire.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.June 25, 2024 | seekingalpha.comInvestor Day SlidesJune 13, 2024 | seekingalpha.comOcular Therapeutix, Inc. (OCUL) Investor Day Call TranscriptJune 13, 2024 | globenewswire.comOcular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR StudyJune 5, 2024 | globenewswire.comOcular Therapeutix® to Host Investor Day on June 13, 2024June 4, 2024 | globenewswire.comOcular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2024 | seekingalpha.comOcular Therapeutix: Betting On Axpaxli For A Major Market BreakthroughJune 1, 2024 | seekingalpha.comOcular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 ResultsMay 29, 2024 | markets.businessinsider.comIcecure Medical: Strong Sales Growth and Promising Regulatory Prospects Underpin Buy RatingMay 15, 2024 | finance.yahoo.comOcular Therapeutix Inc Reports First Quarter 2024 EarningsSee More Headlines Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees230Year FoundedN/APrice Target and Rating Average Stock Price Target$15.83 High Stock Price Target$22.00 Low Stock Price Target$11.00 Potential Upside/Downside+89.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,740,000.00 Net Margins-192.61% Pretax Margin-192.61% Return on Equity-76.64% Return on Assets-36.33% Debt Debt-to-Equity Ratio0.16 Current Ratio21.39 Quick Ratio21.29 Sales & Book Value Annual Sales$58.44 million Price / Sales22.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book10.59Miscellaneous Outstanding Shares154,890,000Free Float146,370,000Market Cap$1.30 billion OptionableOptionable Beta1.30 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Antony Mattessich (Age 56)President, CEO & Director Comp: $1.05MMr. Donald Notman Jr.Chief Financial OfficerDr. Jeffrey S. Heier M.D. (Age 63)Chief Scientific Officer Comp: $84.88kDr. Rabia Gurses Ozden M.D. (Age 55)Chief Medical Officer Comp: $621.39kDr. Pravin U. Dugel M.D. (Age 60)Executive Chairman Dr. Karen-Leigh Edwards M.B.A.Ph.D., Chief Operations OfficerDr. Peter K. Jarrett Ph.D. (Age 67)Chief Technology Officer Mr. Philip C. Strassburger Esq. (Age 64)General Counsel Comp: $282.61kMr. William H. Ransone IIVice President of Global Sales & MarketingMs. Tracy SmithVice President of Human ResourcesMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVASupernus PharmaceuticalsNASDAQ:SUPNPliant TherapeuticsNASDAQ:PLRXPhathom PharmaceuticalsNASDAQ:PHATTheravance BiopharmaNASDAQ:TBPHView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 164,383 shares on 7/26/2024Ownership: 0.320%Deltec Asset Management LLCBought 226,181 shares on 7/16/2024Ownership: 1.672%Rosalind Advisors Inc.Bought 750,000 shares on 7/12/2024Ownership: 0.484%Dudley & Shanley Inc.Bought 16,200 shares on 7/9/2024Ownership: 0.010%Opaleye Management Inc.Bought 583,138 shares on 5/29/2024Ownership: 4.295%View All Insider TransactionsView All Institutional Transactions OCUL Stock Analysis - Frequently Asked Questions How have OCUL shares performed this year? Ocular Therapeutix's stock was trading at $4.46 at the beginning of the year. Since then, OCUL stock has increased by 89.0% and is now trading at $8.43. View the best growth stocks for 2024 here. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.06. The biopharmaceutical company earned $14.77 million during the quarter, compared to analyst estimates of $15.43 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 76.64% and a negative net margin of 192.61%. Who are Ocular Therapeutix's major shareholders? Top institutional shareholders of Ocular Therapeutix include Deltec Asset Management LLC (1.67%), Rosalind Advisors Inc. (0.48%), Bank of New York Mellon Corp (0.32%) and Dudley & Shanley Inc. (0.01%). Insiders that own company stock include Summer Road Llc, Antony C Mattessich, Sanjay Nayak, Donald Notman, Philip C Strassburger, Christopher G White and Rabia Gurses Ozden. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER) and Gilead Sciences (GILD). This page (NASDAQ:OCUL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCUL Stock Alerts